NEW YORK – Friday evening, the Supreme Court of the United States (SCOTUS) said that the abortion pill mifepristone will remain widely available for now, delaying the potential for a swift end to widespread availability of this medication that is used in more than half of abortions in the country.
The Supreme Court granted the stay requested by the Department of Justice (DOJ) and pharmaceutical company Danco in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al. allowing mifepristone’s FDA approval to remain unchanged as the case proceeds through the Fifth Circuit Court of Appeals and the Supreme Court.
Wendy Stark, President & CEO, Planned Parenthood of Greater New York in a statement said, “While we can breathe a sigh of relief today, we know the fight for our bodily autonomy and widespread access to abortion care is far from over. Anti-abortion actors are relentlessly working to completely ban abortion in this country. Everyone should have the ability to make decisions about their own reproductive lives and futures, including choosing the method of abortion that works best for them. Today’s decision affirms that mifepristone is a safe and effective option for abortion and medical treatment of miscarriage.
“At Planned Parenthood of Greater New York, our doors remain open for all who need sexual and reproductive health care – which will always include abortion, no matter what. We will continue to do everything in our power to guarantee safe and equal access to all
methods of abortion for all.”